Emerging role of RAB GTPases in cancer and human disease.

Emerging evidence implicates alterations in the RAB small GTPases and their associated regulatory proteins and effectors in multiple human diseases including cancer. We have recently shown that RAB25, located at chromosome 1q22, is amplified at the DNA level and overexpressed at the RNA level in ovarian and breast cancer. These changes correlated with a worsened outcome in both diseases. In addition, enforced expression of RAB25 in both breast and ovarian cancer cells decreased apoptosis and increased proliferation and aggressiveness in vivo, potentially explaining the worsened prognosis. A better understanding of genetic alterations as well as the physiologic and pathophysiologic roles of RAB GTPases may open new opportunities for therapeutic intervention and better outcomes.

[1]  Mike Rossner,et al.  Show me the data , 2007, The Journal of cell biology.

[2]  G. Mills,et al.  The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers , 2004, Nature Medicine.

[3]  Wayne A. Phillips,et al.  Mutation of the PIK3CA Gene in Ovarian and Breast Cancer , 2004, Cancer Research.

[4]  W. Hahn,et al.  A Genetically Defined Model for Human Ovarian Cancer , 2004, Cancer Research.

[5]  D. Albertson.  Profiling Breast Cancer by Array CGH , 2003, Breast Cancer Research and Treatment.

[6]  A. Wandinger-Ness,et al.  Rab proteins and endocytic trafficking: potential targets for therapeutic intervention. , 2003, Advanced drug delivery reviews.

[7]  Trevor Hastie,et al.  Gene expression patterns in ovarian carcinomas. , 2003, Molecular biology of the cell.

[8]  A. Regev,et al.  Molecular analysis of transitional cell carcinoma using cDNA microarray , 2003, Oncogene.

[9]  C. Thompson,et al.  Rab7 prevents growth factor-independent survival by inhibiting cell-autonomous nutrient transporter expression. , 2003, Developmental cell.

[10]  W. Mobley,et al.  NGF Signaling in Sensory Neurons Evidence that Early Endosomes Carry NGF Retrograde Signals , 2003, Neuron.

[11]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Wen-Lin Kuo,et al.  Specific keynote: genome copy number abnormalities in ovarian cancer. , 2003, Gynecologic oncology.

[13]  J. Zavadil,et al.  Single cell behavior in metastatic primary mammary tumors correlated with gene expression patterns revealed by molecular profiling. , 2002, Cancer research.

[14]  Cheryl Jorcyk,et al.  Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors. , 2002, Cancer research.

[15]  Yong-jie Lu,et al.  Chromosome 1q expression profiling and relapse in Wilms' tumour , 2002, The Lancet.

[16]  M. Odero,et al.  Genomic imbalances detected by comparative genomic hybridization are prognostic markers in invasive ductal breast carcinomas , 2002, Histopathology.

[17]  P. Courtoy,et al.  The endocytic catalysts, Rab5a and Rab7, are tandem regulators of thyroid hormone production , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  G. Mills,et al.  The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. , 2001, Seminars in oncology.

[19]  S. Korsmeyer,et al.  Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death , 2001, Science.

[20]  A. Fischer,et al.  Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome , 2000, Nature Genetics.

[21]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[22]  I. Nagata,et al.  Gains of 1q21-q22 and 13q12-q14 are potential indicators for resistance to cisplatin-based chemotherapy in ovarian cancer patients. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  S. Korsmeyer,et al.  BCL-2 family members and the mitochondria in apoptosis. , 1999, Genes & development.

[24]  Joe W. Gray,et al.  PIK3CA is implicated as an oncogene in ovarian cancer , 1999, Nature Genetics.

[25]  W. Kuo,et al.  High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays , 1998, Nature Genetics.

[26]  I. Petersen,et al.  Identification of allelic losses in benign, borderline, and invasive epithelial ovarian tumors and correlation with clinical outcome , 1997, Cancer.